316 related articles for article (PubMed ID: 25273092)
21. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
LaBonte MJ; Manegold PC; Wilson PM; Fazzone W; Louie SG; Lenz HJ; Ladner RD
Int J Cancer; 2009 Dec; 125(12):2957-69. PubMed ID: 19536776
[TBL] [Abstract][Full Text] [Related]
22. Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery.
Huang HC; Rizvi I; Liu J; Anbil S; Kalra A; Lee H; Baglo Y; Paz N; Hayden D; Pereira S; Pogue BW; Fitzgerald J; Hasan T
Cancer Res; 2018 Jan; 78(2):558-571. PubMed ID: 29187403
[TBL] [Abstract][Full Text] [Related]
23. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
[TBL] [Abstract][Full Text] [Related]
24. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.
Xu G; Zhang W; Ma MK; McLeod HL
Clin Cancer Res; 2002 Aug; 8(8):2605-11. PubMed ID: 12171891
[TBL] [Abstract][Full Text] [Related]
25. A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38.
Stubdal H; Perin N; Lemmon M; Holman P; Bauzon M; Potter PM; Danks MK; Fattaey A; Dubensky T; Johnson L
Cancer Res; 2003 Oct; 63(20):6900-8. PubMed ID: 14583489
[TBL] [Abstract][Full Text] [Related]
26. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.
Drummond DC; Noble CO; Guo Z; Hong K; Park JW; Kirpotin DB
Cancer Res; 2006 Mar; 66(6):3271-7. PubMed ID: 16540680
[TBL] [Abstract][Full Text] [Related]
27. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.
Govindan SV; Cardillo TM; Moon SJ; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2009 Oct; 15(19):6052-61. PubMed ID: 19789330
[TBL] [Abstract][Full Text] [Related]
28. Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice.
Chu C; Abbara C; Tandia M; Polrot M; Gonin P; Farinotti R; Bonhomme-Faivre L
Fundam Clin Pharmacol; 2014 Dec; 28(6):652-60. PubMed ID: 24588516
[TBL] [Abstract][Full Text] [Related]
29. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.
Pavillard V; Agostini C; Richard S; Charasson V; Montaudon D; Robert J
Cancer Chemother Pharmacol; 2002 Apr; 49(4):329-35. PubMed ID: 11914913
[TBL] [Abstract][Full Text] [Related]
30. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
[TBL] [Abstract][Full Text] [Related]
31. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
Heske CM; Mendoza A; Edessa LD; Baumgart JT; Lee S; Trepel J; Proia DA; Neckers L; Helman LJ
Oncotarget; 2016 Oct; 7(40):65540-65552. PubMed ID: 27608846
[TBL] [Abstract][Full Text] [Related]
32. Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts.
Zamboni WC; Jung LL; Egorin MJ; Hamburger DR; Joseph E; Jin R; Strychor S; Ramanathan RK; Eiseman JL
Clin Cancer Res; 2005 Jul; 11(13):4867-74. PubMed ID: 16000585
[TBL] [Abstract][Full Text] [Related]
33. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.
Emmink BL; Van Houdt WJ; Vries RG; Hoogwater FJ; Govaert KM; Verheem A; Nijkamp MW; Steller EJ; Jimenez CR; Clevers H; Borel Rinkes IH; Kranenburg O
Gastroenterology; 2011 Jul; 141(1):269-78. PubMed ID: 21459094
[TBL] [Abstract][Full Text] [Related]
34. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
Metz MZ; Gutova M; Lacey SF; Abramyants Y; Vo T; Gilchrist M; Tirughana R; Ghoda LY; Barish ME; Brown CE; Najbauer J; Potter PM; Portnow J; Synold TW; Aboody KS
Stem Cells Transl Med; 2013 Dec; 2(12):983-92. PubMed ID: 24167321
[TBL] [Abstract][Full Text] [Related]
35. DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies.
Meyer-Losic F; Nicolazzi C; Quinonero J; Ribes F; Michel M; Dubois V; de Coupade C; Boukaissi M; Chéné AS; Tranchant I; Arranz V; Zoubaa I; Fruchart JS; Ravel D; Kearsey J
Clin Cancer Res; 2008 Apr; 14(7):2145-53. PubMed ID: 18381956
[TBL] [Abstract][Full Text] [Related]
36. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.
Harasym TO; Tardi PG; Harasym NL; Harvie P; Johnstone SA; Mayer LD
Oncol Res; 2007; 16(8):361-74. PubMed ID: 17913044
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation.
Prijovich ZM; Burnouf PA; Chou HC; Huang PT; Chen KC; Cheng TL; Leu YL; Roffler SR
Mol Pharm; 2016 Apr; 13(4):1242-50. PubMed ID: 26824303
[TBL] [Abstract][Full Text] [Related]
38. Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer.
Adiwijaya BS; Kim J; Lang I; Csõszi T; Cubillo A; Chen JS; Wong M; Park JO; Kim JS; Rau KM; Melichar B; Gallego JB; Fitzgerald J; Belanger B; Molnar I; Ma WW
Clin Pharmacol Ther; 2017 Dec; 102(6):997-1005. PubMed ID: 28445610
[TBL] [Abstract][Full Text] [Related]
39. Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.
Prijovich ZM; Chen KC; Roffler SR
Mol Cancer Ther; 2009 Apr; 8(4):940-6. PubMed ID: 19372567
[TBL] [Abstract][Full Text] [Related]
40. Functional-segregated coumarin-containing telodendrimer nanocarriers for efficient delivery of SN-38 for colon cancer treatment.
Xu G; Shi C; Guo D; Wang L; Ling Y; Han X; Luo J
Acta Biomater; 2015 Jul; 21():85-98. PubMed ID: 25910639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
